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ABSTRACT Since its emergence in the United States in 2014, enterovirus D68 (EV-D68)
has been and is associated with severe respiratory diseases and acute flaccid myelitis.
Even though EV-D68 has been shown to replicate in different neuronal cells in vitro, it is
currently poorly understood which viral factors contribute to the ability to replicate effi-
ciently in cells of the central nervous system and whether this feature is a clade-specific
feature. Here, we determined the replication kinetics of clinical EV-D68 isolates from
(sub)clades A, B1, B2, B3, and D1 in human neuroblastoma cells (SK-N-SH). Subsequently,
we compared sequences to identify viral factors associated with increased viral replica-
tion. All clinical isolates replicated in SK-N-SH cells, although there was a large difference
in efficiency. Efficient replication of clinical isolates was associated with an amino acid
substitution at position 271 of VP1 (E271K), which was acquired during virus propaga-
tion in vitro. Recognition of heparan sulfate in addition to sialic acids was associated
with increased attachment, infection, and replication. Removal of heparan sulfate re-
sulted in a decrease in attachment, internalization, and replication of viruses with E271K.
Taken together, our study suggests that the replication kinetics of EV-D68 isolates in SK-
N-SH cells is not a clade-specific feature. However, recognition of heparan sulfate as an
additional receptor had a large effect on phenotypic characteristics in vitro. These obser-
vations emphasize the need to compare sequences from virus stocks with clinical iso-
lates in order to retrieve phenotypic characteristics from original virus isolates.
IMPORTANCE Enterovirus D68 (EV-D68) causes mild to severe respiratory disease and is
associated with acute flaccid myelitis since 2014. Currently, the understanding of the
ability of EV-D68 to replicate in the central nervous system (CNS), and whether it is asso-
ciated with a specific clade of EV-D68 viruses or specific viral factors, is lacking. Compar-
ing different EV-D68 clades did not reveal clade-specific phenotypic characteristics. How-
ever, we did show that viruses which acquired a cell culture-adapted amino acid
substitution in VP1 (E271K) recognized heparan sulfate as an additional receptor. Recog-
nition of heparan sulfate resulted in an increase in attachment, infection, and replication in
neuroblastoma cells compared with viruses without this specific amino acid substitution. The
ability of EV-D68 viruses to acquire cell culture-adaptive substitutions which have a large ef-
fect in experimental settings emphasizes the need to sequence virus stocks.
KEYWORDS VP1, cell culture adaptation, enterovirus D68, heparan sulfate, in vitro,
neuroblastoma cells, neurotropism, pathogenesis, replication
Enterovirus D68 (EV-D68) is known to cause mild to severe respiratory infections, butsince 2014 it has been increasingly associated with neurological complications
(1–3). After its discovery in 1962, cases were only sporadically reported (4). EV-D68
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caused a large outbreak of severe respiratory disease across the United States of which
about 10.4% of symptomatic cases developed acute flaccid myelitis (AFM) from August
2014 to January 2015 (5). During this outbreak, more than 2,000 cases of EV-D68
infections were reported in 20 countries (6–9), of which about 7% of symptomatic cases
developed AFM (10). Other neurological complications like cranial nerve dysfunction
and encephalitis were occasionally reported (11–13). Since then, biennial epidemics of
EV-D68 occur globally, with the largest epidemic in 2018 (14–17).
EV-D68 belongs to the Enterovirus genus in the Picornaviridae family. It is a nonen-
veloped, positive-sense, single-stranded RNA virus. Within the capsid, the structural
protein VP1 plays an important role in the attachment to host cells, and its gene is the
most variable part of the genome and used for genotyping (18). Circulating EV-D68
isolates use cell surface glycoproteins including sialylated glycoproteins or glycolipid as
a receptor. These sialylated receptors bind to the canyon in VP1, which leads to
conformational change and subsequent dysregulation of stability and thereby initiates
uncoating (19). However, recent studies have identified nonsialylated receptors, such as
ICAM-5 and heparan sulfate glycosaminoglycans (GAGs), for specific EV-D68 isolates
(20, 21).
To date, EV-D68 is divided into four clades, from A to D, although the initial division
in three clades, A, B, and C, with subclades A1 and A2, is also used. Some researchers
use A for A1 and D for A2 (22, 23). EV-D68 clade B is subdivided into subclades B1, B2,
and B3 (24), and clade D has recently been subdivided into subclades D1 and D2 (25).
Multiple clades circulated during the 2014 outbreak, but subclade B1 was the most
prevalent and was also associated with neurological complications. Based on this
observation, it was initially thought that the ability to invade and replicate in the central
nervous system (CNS) was a recently acquired feature and clade specific (2, 3, 8, 10, 26).
However, since 2016, subclade B3 and to a lesser extent subclade D1 became predom-
inant, and both were associated with neurological complications (16, 27–29). In addi-
tion, recent studies have shown that multiple isolates from different clades are able to
infect both neuronal cells and neuroblastoma cell lines (30) and that non-subclade B1
and B3 isolates were able to cause paralysis in mice after intracranial inoculation.
Interestingly, isolates from the same clade differed in their ability to cause paralysis in
mice (31). Altogether, this suggests that the ability to invade and replicate in the CNS
is not a clade-specific feature. Even though several studies have determined the in vitro
phenotypic characteristics of EV-D68 isolates in cells of the CNS, viral factors associated
with efficient attachment, infection, and replication have not been identified yet. In
addition, genetic analysis of EV-D68 isolates associated with phenotypic characteristics
in vitro has not been carried out in previous studies.
In this study, we investigated the ability of EV-D68 isolates from different clades to
attach and infect human neuroblastoma cells (SK-N-SH) and determined their replica-
tion kinetics. Subsequently, we compared viral sequences in order to identify viral
factors associated with increased viral replication.
RESULTS
Clinical enterovirus D68 isolates from different clades replicate in human
neuroblastoma cells with different efficiency. Growth curves using a multiplicity of
infection (MOI) of 0.01 were generated for clinical isolates of clade A (or A1; here we use
A), subclade B1, subclade B2 (B2/039 and B2/947), subclade B3, subclade D1 (or A2; here
we use D1), and the prototype Fermon strain in SK-N-SH and rhabdomyosarcoma (RD)
cells. Growth curves showed that all viruses replicated in SK-N-SH cells, but virus titers
of subclades B2/947 and B3 and Fermon were significantly higher than those of clade
A and subclades D1, B1, and B2/039 from 24 h postinoculation (hpi) onward (Fig. 1A).
Remarkable, large differences between the two subclade B2 isolates were observed in
growth kinetics on SK-N-SH cells. The same pattern was observed in RD cells, but the
differences among isolates were smaller. Isolates that replicated most efficiently on
SK-N-SH cells also did so in RD cells (Fig. 1B). Overall, these data show that EV-D68
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isolates from all clades are able to replicate in SK-N-SH and RD cells but do so with
different efficiency.
Replication efficiency is associated with percentage of infection. To study
whether the replication efficiency was associated with the infection efficiency of the
different EV-D68 isolates, the percentage of infection was determined by immunoflu-
orescence using an anti-VP1 antibody after incubation of viruses on SK-N-SH and RD
cells with an MOI of 2 for 8 h. Viruses of clade B2/947 and Fermon, and to a lesser extent
B3, which replicated most efficiently in SK-N-SH and RD cells, infected higher percent-
ages of cells than did other isolates (Fig. 2A and B). These results suggest that the
efficient replication measured by the growth kinetics was associated with efficient
infection of cells.
Amino acid differences between viruses of subclade B2. Since we observed a
large difference in the replication kinetics between the two isolates of subclade B2, we
initially performed full genome sequencing analysis of the stocks from B2/039 and
B2/947 isolates. There were 13 amino acid differences between these two viruses: V66A,
R67K, K116R, V166I, R234G, V136M, D140N, E271K, R25K, I37V, K56R, I187V, and S56R
(Table 1). These amino acid differences were present in both structural proteins (VP4,
VP2, VP3, and VP1) and nonstructural proteins (2A, 3C, and 3D).
FIG 1 Growth curves of EV-D68 isolates in SK-N-SH and RD cells. Growth curve of clinical isolates of (sub)clades
A, B1, B2, B3, and D1 and prototype EV-D68 strain Fermon in SK-N-SH cells (A) and RD cells (B) at an MOI of 0.01.
Statistical analysis was performed using the one-way analysis of variance (ANOVA) compared to Fermon. Data are
shown as mean  SD from three independent experiments. *, P  0.05; **, P  0.01; ***, P  0.001.
FIG 2 Infection efficiency of different EV-D68 isolates in SK-N-SH and RD cells. Percentage of infected
SK-N-SH cells (A) and RD cells (B) after infection with clinical isolates from A, B1, B2, B3, and D1 and
prototype EV-D68 strain Fermon 8 h postinfection (MOI of 2). The infected cells were stained for VP1
antigen using immunofluorescence staining. Three high-power fields were captured per sample. Statistical
analysis was performed using the one-way ANOVA in comparison with Fermon. Data are shown as mean 
SD from three independent experiments. *, P  0.05; **, P  0.01; ***, P  0.001.
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A lysine is present at position 271 of capsid protein VP1 in clinical isolates that
replicate efficiently in SK-N-SH and RD cells. After the identification of amino acid
differences between the two clinical isolates of subclade B2, the 13 amino acid
positions that differed were verified in the other clinical isolates to identify amino
acid substitutions possibly associated with increased infection and replication effi-
ciency. A lysine (K) at position 271 in the VP1 capsid protein was observed only in clade
B2/947 and B3 viruses, the two clinical isolates that replicated most efficiently in
SK-N-SH and RD cells. All other clinical isolates had a glutamic acid (E) or valine (V) at
position 271 in VP1, and the lab-adapted Fermon carried an aspartic acid (D) (Table 2).
At all other positions that differed between the clade B2 isolates, no common differ-
ences were observed between the viruses with different replication efficiencies (Ta-
ble 2). This indicates that the amino acid substitution E271K might be a determinant for
increased infection and replication in SK-N-SH cells in vitro.
A lysine at position 271 in VP1 is acquired during in vitro passaging. The clinical
isolates used in this study were passaged in RD cells to produce virus stocks. To
investigate whether a lysine at position 271 in VP1 was present in the original isolate
of the patient, sequences from clinical specimens, previous passages, and virus stocks
used in this study were generated and aligned. In the clinical specimens, a glutamic
acid (E) was found at position 271 in VP1 of both subclade B2/947 (21) and subclade B3.
Furthermore, sequencing analysis of all virus passages showed the acquisition of a
lysine (K) in passage 3 of subclade B2/947 and passage 2 of subclade B3 on RD cells
(Table 3). There were no minor variants present at position 271 of sequences derived
from clinical specimens and stock B2/947 and B3 viruses using a 20% cutoff (Table 3).
This indicates that viruses with high replication and infection efficiency acquired the
E271K amino acid substitution during passaging in RD cells.
Viruses with the E271K substitution in VP1 attached more efficiently to SK-
N-SH and RD cells. Since the amino acid at position 271 of EV-D68 resides within the
canyon, close to the sialic acid binding site (19), we investigated whether EV-D68
isolates with the specific E271K amino acid substitution attached to higher percentages
of SK-N-SH and RD cells. We observed that the subclade B2/947 and subclade B3
isolates which acquired the E271K substitution attached to higher percentages of
SK-N-SH and RD cells than did all other isolates. Fermon attached to lower percentages
of SK-N-SH and RD cells despite efficient replication and infection (Fig. 3A and B).
TABLE 1 Amino acid differences between clade B2/947 and clade B2/039 isolates
Isolate
Amino acid at position in protein
VP4 VP2 VP3 VP1 2A 3C 3D
66 67 116 166 234 136 140 271 25 37 56 187 56
B2/947 A K R I G M N K K V R V R
B2/039 V R K V R V D E R I K I S
TABLE 2 Amino acids present in clinical isolates of (sub)clades A, B1, B2, B3, and D1 and
Fermon at the positions that differed between low- and high-replicating isolates
Isolate
Amino acid at position in protein
VP4 VP2 VP3 VP1 2A 3C 3D
66 67 116 166 234 136 140 271 25 37 56 187 56
B2/947a A K R I G M N K K V R V R
B3a A R K I G V D K R I R V S
B2/039 V R K V R V D E R I K I S
A A K K V R T D E R V K V S
D1 A K K V A M D E R I K V S
B1 A K K I G V D V R V R V S
Fermona A R K I G M D D R V R V S
aIsolates that replicate efficiently in SK-N-SH cells.
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Overall, these observations suggest that the E271K substitution is associated with
increased virus attachment in vitro.
Viruses with E271K substitution in VP1 recognize sialic acid and heparan
sulfate. A previous study has shown that among several EV-D68 strains, subclade
B2/947 can recognize heparan sulfate as an additional receptor to sialic acid (21). To
investigate whether our viruses with an E271K substitution were able to recognize both
sialic acid and heparan sulfate, we determined the ability of these viruses to attach to
cells that were pretreated with Arthrobacter ureafaciens neuraminidase and heparinase
III to remove sialic acids or heparan sulfate, respectively. Subclade B2/947 and B3
isolates carrying the E271K substitution, and the subclade B2/039 isolate (271E) as
control, were included in these analyses. Removal of sialic acids and heparan sulfate
was confirmed by measuring mean fluorescent intensity (MFI) with Maackia amurensis
lectin (MAL) for (2,3)-linked sialic acid and Sambucus nigra lectin (SNA) (2,6)-linked
sialic acid, and with an antibody that recognizes heparan sulfate (Fig. 4A and D). The
percentage of cells to which the virus attached was significantly decreased for all
viruses in both SK-N-SH and RD cells after neuraminidase treatment (Fig. 4B and C). In
contrast, heparinase III treatment resulted in decreased attachment of only viruses with
the E271K substitution (Fig. 4E and F). Overall, these results showed that the viruses
with the E271K substitution recognize both sialic acid and heparan sulfate on the
cellular surface.
Attachment, internalization, and replication of viruses with E271K substitution
in VP1 depend in part on heparan sulfate recognition. To investigate if heparan
sulfate is required for attachment, internalization, and replication of viruses with an
E271K substitution, heparan sulfate was removed on SK-N-SH and RD cells by either
TABLE 3 Amino acid at position 271 of VP1 in isolates B2/947 and B3 from original clinical specimens and historical passages
Isolate
Clinical specimen/
virus isolate passage Amino acid at position 271 Frequent variant; method
GenBank
accession no.
B2/947 Clinical specimen E 100%; Illumina
Passage 1 Position not sequenced
Passage 2 E 100%; Sanger KT231897
Passage 3 K 100%; Sanger KT231898
Passage 4 K 100%; Illumina MN954540
B3 Clinical specimen E 100%; Sanger
Passage 1 E 100%; Sanger
Passage 2 K 100%; Illumina
Passage 3 K 100%; Illumina
Passage 4 K 100%; Illumina MN954541
FIG 3 Virus attachment of EV-D68 viruses to SK-N-SH and RD cells. Experiments were performed using flow cytometry.
Attachment of clinical isolates from (sub)clades A, B1, B2, B3, and D1 and prototype strain Fermon to SK-N-SH cells (A) and
RD cells (B). Heat-inactivated viruses were included as negative control. Statistical analysis was performed using the
one-way ANOVA in comparison to Fermon. Data are shown as mean  SD from three independent experiments. *,
P  0.05; **, P  0.01; ***, P  0.001.
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heparinase III or NaClO3, which prevents cell surface sulfation (21). Treated and un-
treated cells were inoculated with an MOI of 1 of B2/947, B3, and B2/039. After 1 hpi
at 37°C, the amount of attached and internalized viral RNA of B2/947 and B3 was
smaller in the heparinase III- or NaClO3-treated cells than in untreated cells by qPCR.
Viral RNA for B2/039 was not reduced in the heparinase- or NaClO3-treated cells, with
the exception of a minimal but significant reduction of viral RNA in SK-N-SH cells
treated with NaClO3 but not in RD cells (Fig. 5A and B). Virus replication of both B2/947
and B3 was significantly decreased in SK-N-SH and RD cells treated with heparinase III
or NaClO3, while replication levels of B2/039 were similar in treated and untreated cells
(Fig. 5C and D; see also Fig. S1 in the supplemental material). Together, these results
indicate that the recognition of heparan sulfate is important for facilitating virus
attachment, internalization, and replication.
DISCUSSION
Here, we report that EV-D68 isolates from (sub)clades A, B1, B2, B3, and D1
replicated in human neuroblastoma SK-N-SH cells; however, large differences were
observed in replication efficiency. Subsequent genotypic analysis revealed that viruses
replicating most efficiently had a specific amino acid substitution in VP1 (E271K). This
substitution was acquired during cell culture propagation and was associated with the
recognition of heparan sulfate. Furthermore, attachment, internalization, and replica-
tion depended in part on heparan sulfate recognition for viruses with the E271K
substitution in VP1. These findings suggest that efficient replication of EV-D68 isolates
in vitro in human neuroblastoma cells is not a clade-specific feature but at least in part
associated with the usage of heparan sulfate as an additional receptor.
The amino acid substitution at position 271 of VP1 (E271K) acquired during in vitro
passaging in 2 out of the 6 viruses included in our study was associated with the
recognition of heparan sulfate as an additional receptor (21), which had a large impact
on the phenotypic characteristics of EV-D68 viruses. Heparan sulfate is abundantly
FIG 4 Virus attachment of clinical isolates B2/039, B2/947, and B3 after neuraminidase and heparinase III treatment. (A) Mean fluorescent intensity (MFI) levels
of MAL [(2,3)-linked sialic acid] and SNA [(2,6)-linked sialic acid] with and without neuraminidase treatment. (B and C) Percentage of attachment of isolates
B2/039, B2/947, and B3 with and without neuraminidase treatment of SK-N-SH cells (B) and RD cells (C). (D) MFI levels of heparan sulfate with and without
heparinase III treatment. (E and F) Attachment of clinical isolates B2/039, B2/947, and B3 with and without heparinase III treatment on SK-N-SH cells (E) and
RD cells (F). Statistical analysis was performed by paired t test. Data are shown as mean  SD from three independent experiments. *, P  0.05; **, P  0.01;
***, P  0.001.
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expressed on RD cells (32) and associated with increased virus attachment, infection
efficiency, and virus replication in cells in vitro. The ability of EV-D68 to replicate in
mouse neuroblastoma cells and human induced pluripotent stem cell motor neurons
were independent of sialic acid recognition, although the usage of heparan sulfate was
not investigated (30, 33). In our study, unfortunately, viruses from earlier passages
without E271K in VP1 were not available and an infectious clone of the clinical isolate
B2/947 with the original VP1 amino acid E271 could not be recovered (21), which made
a direct comparison of viruses with and without E271K in VP1 not possible. The lysine
at position 271 of VP1 is positively charged, which contributes to the formation of a
basic patch that interacts with negatively charged heparan sulfate proteoglycan (21).
This mechanism has been described previously for other picornaviruses which acquired
the recognition of heparan sulfate during passaging of viruses in vitro (34–36).
It was initially thought that the neurotropic potential of EV-D68 was a feature
recently acquired and was associated with subclade B1. However, epidemiological and
clinical data have shown that different subclades, namely, B3 and D1, besides subclade
B1 have also been associated with AFM cases after 2014 (16, 28, 29). In addition, most
in vitro studies, including ours, and in vivo studies do not reveal phenotypic difference
between clades or recent and older EV-D68 isolates (30, 31, 37). In vivo, EV-D68 isolates
from multiple clades (e.g., clade A and subclade B1) were able to cause paralysis after
intracranial inoculation (31). In vitro, we and others showed that EV-D68 isolates from
multiple clades were able to replicate in neuroblastoma cells (37). Furthermore, we did
not detect phenotypic differences between viruses isolated before and after 2014
independent of the clade, which correlates with the study by Rosenfeld et al. (30), but
not with a study performed by Brown et al. (37). Unfortunately, virus stocks were not
compared with clinical isolates in these studies. All together, these data suggest that
the ability to replicate in cells of the CNS is not a clade-specific feature.
FIG 5 Attachment, internalization, and replication of clinical isolates B2/947, B3, and B2/039 in SK-N-SH and RD cells after
heparinase III and NaClO3 treatment. SK-N-SH and RD cells were treated for 1 h with heparinase III, or cells were cultured
for 5 days with NaClO3. After the treatment, cells were infected with clinical isolates at an MOI of 1. To remove the unbound
viruses, cells were washed 3 times with PBS before cell lysis. Attached and intracellular viral RNA levels were determined
by qPCR 1 h postinfection. Percentages of viral RNA levels were compared to values for untreated cells in SK-N-SH cells (A)
and RD cells (B). Infectious virus particles of the supernatants from SK-N-SH cells (C) and RD cells (D) were determined by
TCID50 10 h postinfection. Statistical analysis was performed using the one-way ANOVA. Data are shown as mean  SD
from three independent experiments. *, P  0.05; **, P  0.01; ***, P  0.001.
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The role of heparan sulfate as an additional receptor in the pathogenesis in vivo
remains unclear. Although the presence of the E271K substitution in human EV-D68
isolates has not been studied, we found that only a very few EV-D68 VP1 sequences
available in GenBank have a lysine at position 271 of VP1 (by 15 December 2019, 17 out
of 1,737 [1%]), and they fall in a wide range of old and current clades. However, of
most sequences the source, clinical material or virus isolate, and passage history are not
known. Interestingly, acquisition of heparan sulfate recognition in an immunocompro-
mised patient with enterovirus 71 (EV-71) was associated with systemic spread, includ-
ing the CNS. In this patient a mutation in the VP1 responsible for heparan sulfate
recognition was detected only in extrarespiratory samples (38). Since heparan sulfate is
not expressed on the apical side of respiratory epithelial cells, but abundantly in cells
outside the respiratory tract, such as cells of the CNS and muscle cells (38, 39), in vivo
acquisition of E271K might—just like EV-71— occur outside the respiratory tract and
would therefore hardly be found in respiratory samples. Sequence analysis of respira-
tory and extrarespiratory samples from the same patient should reveal if heparan
sulfate recognition is important for the pathogenesis of EV-D68 in vivo.
It remains unclear why there has been an increase of AFM cases associated with
EV-D68 since 2014, since epidemiological and serological studies suggest that EV-D68
has been circulating throughout the population for decades (40, 41). Currently, the
pathogenesis of neurological disease associated with EV-D68 infection is not fully
understood. Either a direct effect of virus entry and replication in the nervous system
or an indirect effect of systemic cytokines could contribute. However, the detection of
EV-D68 or virus-specific antibodies in the cerebrospinal fluid suggests that virus enters
and replicates in the CNS in at least some of the patients (42, 43). As there have been
more cases with severe respiratory disease caused by EV-D68 since 2014 (9, 44), it might
be that recent EV-D68 viruses replicate to higher titers in the respiratory tract, thereby
increasing the risk of systemic spread including that to the CNS. However, understand-
ing the exact mechanism of systemic spread of EV-D68 in vivo requires more in-depth
pathogenesis studies.
Taken together, we demonstrate that the replication of EV-D68 isolates in the
neuroblastoma cell line SK-N-SH is not a clade-specific phenotype of EV-D68. However,
large phenotypic differences that we did observe in vitro could be linked to the
substitution E271K in VP1 leading to the recognition of heparan sulfate as an additional
receptor, which resulted in increased attachment, internalization, and replication.
Therefore, we recommend sequencing of virus stocks in order to obtain viruses that
resemble clinical isolates in order to study phenotypic characteristics of EV-D68 isolates
in vitro and in vivo.
MATERIALS AND METHODS
Cells. Rhabdomyosarcoma (RD cells) (ATCC) were maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Lonza, Basel, Switzerland) supplemented with 10% (vol/vol) fetal calf serum (FCS; Sigma-Aldrich,
St. Louis, MO, USA), 100 IU/ml penicillin (Lonza), 100 IU/ml streptomycin (Lonza), and 2 mM L-glutamine
(Lonza), at 37°C with 5% CO2. SK-N-SH neuroblastoma cells (Sigma-Aldrich) were maintained in Eagle’s
minimum essential medium (EMEM) and Earle’s balanced salt solution (EBSS) (Lonza), 10% (vol/vol) FCS,
100 IU/ml penicillin (Lonza), 100 g/ml streptomycin (Lonza), 2 mM L-glutamine (Lonza), 1% nonessential
amino acids (Lonza), 1 mM sodium pyruvate (Thermo Fisher Scientific, Waltham, MA, USA), and 1.5 mg/ml
sodium bicarbonate (Lonza), at 37°C with 5% CO2. All SK-N-SH cells used in the study were from the same
batch and maintained up to 15 passages.
Viruses. Enterovirus D68 viruses included in this study were isolated from clinical specimens at the
National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands. The viruses
were initially isolated on RD cells at 33°C at RIVM from patients with respiratory disease caused by EV-D68
infection. Virus stocks for the in vitro studies were grown at the Viroscience laboratory, Erasmus MC
(EMC), Rotterdam, The Netherlands, in RD cells (ATCC) at 33°C in 5% CO2. The viruses included in this
study, with virus reference number, year of collection and isolation, passage number, and accession
number are as follows: clade A (or A1) (4311200821; 2012, passage RD3, accession number MN954536)
(45), D subclade D1 (or A2) (4311400720; 2014, passage RD4, accession number MN954537) (45), B1
(4311300117; 2013, passage RD4, accession number MN954538 (45), B2/039 (4311201039; 2012, passage
RD3, accession number MN954539) (45), B2/947 (4310900947; 2009, passage RD4, accession number
MN954540 (19, 46), and B3 (4311601013; 2016, passage RD4, accession number MN954541). EV-D68
prototype Fermon was provided by Frank van Kupperveld, Utrecht University, Utrecht, The Netherlands.
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Virus titrations. Virus titers (median tissue culture infectious dose [TCID50]) of the virus stocks were
determined by endpoint titrations in RD cells. Briefly, 10-fold serial dilutions were made and inoculated
onto a monolayer of RD cells. The inoculated plates were incubated at 33°C in 5% CO2. Cytopathic effect
(CPE) was determined at day 5, and virus titers were determined using the Spearman-Kärber method (47).
Replication kinetics, virus infection, and internalization. Virus infection by EV-D68 isolates was
determined using a multiplicity of infection (MOI) of 0.01 or 1. Monolayers of SK-N-SH and RD cells in a
6-well plate or a 96-well plate were inoculated with the different EV-D68 viruses for 1 h at 37°C in 5% CO2
or cell culture medium as a control. After 1 h of virus adsorption, the inoculum was removed, and cells
were washed once with PBS before the cells were lysed with lysis buffer (Roche, The Netherlands) for
qPCR analysis or replenished with culture medium and incubated at 37°C in 5% CO2. The supernatant was
collected at the indicated hour postinoculation (hpi) and stored at 80°C for subsequent virus titration.
Percentage of infections. SK-N-SH and RD cells (80% confluent) in a 96-well plate were infected
with EV-D68 at an MOI of 2. Mock-infected cells were included as a negative control. EV-D68-infected
SK-N-SH and RD cells were incubated at 37°C and 33°C in 5% CO2, respectively. After 8 hpi, cells were
fixed with 4% paraformaldehyde (PFA) for 20 min at room temperature, washed with PBS, and
permeabilized with 70% ethanol. Cells were first incubated with 5% bovine serum albumin (BSA; Aurion,
Wageningen, The Netherlands) in PBS for 30 min before incubation with rabbit anti-EV-D68 VP1
(20 g/ml; GeneTex, Irvine, CA, USA) for 1 h. Cells were washed twice with PBS and incubated with goat
anti-rabbit IgG conjugated with Alexa Fluor 594 (10 g/ml; Life Technologies, Inc., The Netherlands) in
PBS with 0.1% BSA (Aurion) for 1 h. Cells were washed 3 times with PBS and mounted with ProLong
Diamond Antifade with DAPI (4=,6-diamidino-2-phenylindole; Life Technologies) to visualize nuclei. Each
experiment included negative and omission controls. EV-D68 VP1-positive cells were identified using a
Zeiss LSM 700 laser scanning microscope. All images were processed using Zen 2010 software. Per
sample, 3 high-power fields were photographed, and the number of infected cells was calculated by
counting virus-infected/uninfected cells in 3 randomly chosen panels. All experiments were performed
in triplicate.
Next-generation sequencing. After pretreatment of the virus stock with OmniCleave (Lucigen,
Halle-Zoersel, Belgium), RNA was extracted using the NucleoSpin RNA II kit (Bioke, Leiden, The Nether-
lands) according to the manufacturer’s instructions. First-strand cDNA was synthesized from using
random hexamers and Superscript IV (Thermo Fisher Scientific). Double-stranded DNA was generated
using Klenow fragment (New England Biolabs [NEB]). For library preparation, the Kapa HyperPlus library
preparation kit (Roche, Basel, Switzerland) was used according to the manufacturer’s instructions with
minor modifications. Adapters were diluted 1:10, and a second wash step was performed after adapter
ligation. The samples were sequenced on an Illumina MiSeq to generate 2  300-bp sequence reads.
Data analysis for Illumina sequencing. Raw sequence reads were quality controlled using fastp
(48). The quality-controlled reads were normalized using bbnorm (49) and subsequently de novo
assembled using SPAdes (50). Minimap2 (51) was used to align the quality-controlled reads against the
obtained contigs and the obtained bam files were loaded into Geneious (52) for minor variant deter-
mination with a 20% cutoff.
Sequencing alignment. Each segment of viral genome was aligned using the CLUSTAL W algorithm
in MEGA5 (53). Next, sequences of all individual isolated were aligned using the BioEdit version 7.0. The
5= untranslated region or noncoding region was resected from sequences.
Virus attachment. Cell suspensions of SK-N-SH or RD cells were incubated with EV-D68 strains for
1 h at 4°C using an MOI of 1. As a negative control, viruses were heat inactivated at 62°C for 10 min before
incubation with the cells. Subsequently, cells were washed with PBS, fixed with 4% PFA for 15 min, and
blocked for 30 min with PBS containing 5% normal goat serum (Dako, Denmark). Cells were incubated
with rabbit anti-EV-D68 VP1 (20 g/ml; GeneTex) in 2 mM EDTA (Sigma-Aldrich) and 0.1% BSA (Aurion)
fluorescence-activated cell sorting (FACS) buffer for 1 h at 4°C. After washing 3 times, cells were
incubated with a secondary goat-anti rabbit IgG conjugated to Alexa Fluor 594 (10 g/ml; Life Technol-
ogies) in FACS buffer. After incubation, cells were washed 3 times in FACS buffer and analyzed using a
BD FACS Lyrics flow cytometer (BD Bioscience, USA). The percentage of cells to which virus attached was
determined using FlowJo 10 software (Ashland, OR, USA). Experiments were performed at least 3 times,
and each experiment was performed in duplicate.
Removal of cell surface sialic acid and heparan sulfate. Cell suspensions of SK-N-SH or RD cells
were incubated with 100 mU/ml Arthrobacter ureafaciens neuraminidase (Roche) or 10 mIU/ml hepari-
nase III (Sigma-Aldrich) in serum-free medium for 1 h at 37°C. To prevent the cell surface sulfation, cells
were cultured for 5 days with 80 mM sodium chlorate (NaClO3; Sigma-Aldrich, 1.06420 EMD Millipore).
Removal of (2,3)-linked sialic acid and (2,6)-linked sialic acid on the cell surface was confirmed by
staining with fluorescein-labeled Sambucus nigra lectin (SNA) (5 g/ml; Vector Laboratories, CA, USA) and
biotinylated Maackia amurensis lectin (MAL) I (5 g/ml; Vector Laboratories). The sialylated cells were
detected by streptavidin-conjugated Alexa Fluor 488 (5 g/ml; Thermo Fisher Scientific). Removal of
heparan sulfate on the cell surface was confirmed using a mouse anti-heparan sulfate monoclonal
antibody (10 g/ml; Amsbio, Frankfurt, Germany). No-virus inoculation control and virus inoculation in
nonenzymatic treatment control were included as a negative control and positive control, respectively,
in all assays. Mean fluorescence intensity (MFI) was measured with BD FACS Lyrics (BD Bioscience).
Subsequently, virus attachment was determined as described above. Data were analyzed using FlowJo
10 software (Ashland, OR, USA). The experiments were performed at least 3 times, and each experiment
was performed in duplicate.
RT-qPCR. Total nucleic acid was extracted from cell lysis using the Magna Pure MagNA Pure LC total
nucleic acid isolation kit (Roche) according to manufacturer’s instructions. The total nucleic acid was
EV-D68 Replication in Neuroblastoma Cells
November/December 2020 Volume 5 Issue 6 e00941-20 msphere.asm.org 9
 on F








eluted in 50 l. For viral RNA quantification, a real-time TaqMan RT-PCR assay was performed using the
Applied Biosystems 7500 real-time PCR system (Thermo Fisher Scientific). The experiments were carried
out by adding forward and reverse EV-D68 primer (75 pmol/l) and the probes (10 pmol/l). The
following sequences including EV-D68 specific primer and probe were used: forward primer 5=-TGTTCC
CACGGTTGAAAACAA-3=, reverse primer 5=-TGTCTAGCGTCTCATGGTTTTCAC-3=, probe 1 5=-TCCGCTATAG
TACTTCG-3=, and probe 2 5=-ACCGCTATAGTACTTCG-3=. The following reaction conditions were applied
for all PCR experiments: 5 min at 50°C and 20 s at 95°C, followed by 45 cycles at 95°C for 3 s, and 60°C
for 31 s.
Statistical analyses. Statistical analyses were performed using GraphPad Prism 6.0 software (La Jolla,
CA, USA). Specific tests are described in the figure legends. P values of 0.05 were considered significant.
All data were expressed as means  standard deviations (SDs). Experiments were performed at least in
biological triplicates and technical duplicates.
Data availability. The viruses included in this study are available under accession numbers
MN954536, MN954537, MN954538, MN954539, MN954540, and MN954541.
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